Clinical trial · Observational
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
NCT05292443CI-TRIAL-00074318withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants were enrolled
Summary
Brief summary (as posted)
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Combined Hepatocellular-cholangiocarcinoma | Combined Hepatocellular Carcinoma and Cholangiocarcinoma | ALIAS | 0.90 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Intrahepatic Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Primary Liver Cancer | Cholangiocarcinoma | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS: Progression-free survival
- timeFrame
- 24 months
- description
- The time length from the date of randomization to any of the following events: disease progression or death from any cause.
Secondary outcomes (3)
- measure
- ORR: Objective Response Rate
- timeFrame
- 24 months
- description
- The proportion of patients with complete response or partial response.
- measure
- OS: Overall Survival
- timeFrame
- 24 months
- description
- The time length from the date of randomization to the date of death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Primary liver cancer diagnosed according to the clinical diagnostic criteria, or histopathological or cytological examination; * 18-80 years old, no limit on gender; * ECOG performance status of 0-2, with expected survival time of more than 12 weeks; * According to RECIST V1.1, there must be at least one measurable lesion; * Patients who are suitable for ICIs treatment and willing to comply with required protocols and give permission to use the data for clinical research and products development; * Patients who join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up. Exclusion Criteria: * Patients with other primary cancers; * Patients with a severe parenchymal disease and unable to accept ICIs treatment; * Patients with a psychiatric disorder and unable to comply with this study; * Patients with symptomatic brain metastasis, anticipated complications or cognitive disorders that are associated with brain metastasis; * Adverse events related to prior anti-tumor treatment (except for hair loss of any grade) did not return to grade 1 or better; * History of cells or organ transplantation; * History of hypersensitivity to the drug administered in this study or contrast media for CT and MRI; * Patients who accepted hepatic local therapy (including ablation therapy, percutaneous injection of ethanol or acetic acid (PEI/PAI), high-intensity focused ultrasound (HIFU), transarterial chemoembolization (TACE)) within 14 days prior to initiation of the study; * Other reasons that the researchers think not suitable for ICIs treatment
References
Publications (0)
Data not yet available
No reference posted for this study.